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There is a transient increase in intracranial pressure (ICP) 18–24 h after ischaemic stroke
in rats, which is prevented by short-duration hypothermia using rapid cooling methods.
Clinical trials of long-duration hypothermia have been limited by feasibility and associated
complications, which may be avoided by short-duration cooling. Animal studies have
cooled faster than is achievable in patients. We aimed to determine whether gradual
cooling at a rate of 2◦C/h to 33◦C or 1◦C/h to 34.5◦C, with a 30min duration at target
temperatures, prevented ICP elevation and reduced infarct volume in rats. Transient
middle cerebral artery occlusion was performed, followed by gradual cooling to target
temperature. Hypothermia to 33◦C prevented significant ICP elevation (hypothermia
1ICP = 1.56 ± 2.26 mmHg vs normothermia 1ICP = 8.93 ± 4.82 mmHg; p = 0.02)
and reduced infarct volume (hypothermia= 46.4± 12.3 mm3 vs normothermia= 85.0±
17.5 mm3; p = 0.01). Hypothermia to 34.5◦C did not significantly prevent ICP elevation
or reduce infarct volume. We showed that gradual cooling to 33◦C, at cooling rates
achievable in patients, had the same ICP preventative effect as traditional rapid cooling
methods. This suggests that this paradigm could be translated to prevent delayed ICP
rise in stroke patients.
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INTRODUCTION
Stroke is the second leading cause of death worldwide and the number one cause of permanent
disability in adults (1, 2). A good collateral flow network is associated with better neurological
outcome after stroke (3, 4). The collateral circulation provides residual perfusion to the “at-risk”
penumbral tissue and slows down the progression of the infarct core.
Dramatic elevations in intracranial pressure (ICP) occur after experimental ischaemic stroke
in animals - in young and aged rats, as well as rats of different strains (5–7). Our preliminary
data indicates a significant ICP rise also occurs in stroke patients at 24 h (8). This ICP rise is a
potential mechanism for collateral failure associated with delayed infarct expansion, worsening
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stroke outcome in patients (9, 10). We have previously shown
that an increase in ICP causes a dramatic decrease in collateral
blood flow and may therefore be responsible for collateral failure
(9). Experimental studies have shown that ICP elevation occurs
even after small strokes (5, 6, 11, 12) which may explain why
it has gone unnoticed in patients with minor stroke, as ICP is
normally only measured in large hemispheric stroke, due to the
invasive nature of the procedure (13). Short-duration therapeutic
hypothermia is a potent, easily implemented strategy that we
have recently shown to have robust efficacy in preventing ICP
elevation 24 h after stroke in rats (5–7). Multiple previous studies
have shown that hypothermia also reduces infarct volume and
improves functional outcome after experimental stroke (14),
although at the time of these studies the effect on ICP was
unknown, and the presumed mechanism of neuroprotection was
bymodification of a wide range of cell deathmechanisms (14, 15).
The effects of hypothermia on ICP elevation therefore suggests
that direct effects on tissue perfusion via collateral vessels may
be an important mechanism of hypothermic cytoprotection.
Several early-phase clinical stroke trials using hypothermia as a
treatment measure have shown feasibility. However, there is a
significant mismatch in cooling duration used in clinical studies,
from that shown to be effective in many experimental studies
(16). Clinical trials of hypothermia have an average cooling
duration of 24 h, with many maintaining hypothermia for up to
72 h (15). In contrast, the vast majority of experimental studies
have cooled for 1–6 h (14). Additionally, rodent studies typically
achieve target temperature within 10–20min (14), a rate that
cannot be achieved when cooling a human. The necessity of long-
duration hypothermia to achieve therapeutic outcome in stroke is
questionable. Current protocols resulted from very early clinical
studies in patients with extremely large, “malignant” middle
cerebral artery (MCA) infarcts, in whom rebound ICP elevation
during rewarming was extremely problematic, and on occasion
fatal (17). However, these durations are logistically extremely
challenging, and increase the risk of complications such as
pneumonia (18). Moreover, our experimental data suggests
short-duration cooling may prevent rebound ICP elevation, thus
obviating the need for very prolonged rewarming. The mismatch
between protocols shown to be effective in experimental studies,
and those tested in clinical trials, needs to be addressed if
there is any hope of translating therapeutic hypothermia for
stroke treatment.
We hypothesized that a clinically achievable gradual cooling
protocol may require even less time at target temperature than
current methods to prevent ICP elevation post-stroke. A milder
target temperature for a short duration is easier to achieve and
would potentially increase feasibility. We previously showed that
hypothermia to 35◦C did not lead to a significant increase in ICP
24 h after stroke. However, a slight ICP rise was seen, suggesting
that 35◦Cmay be close to the threshold for hypothermia ICP rise
prevention (6).
We aimed to determine the benefits of ultra-short duration
hypothermia at target temperature on both ICP elevation and
infarct volume reduction post-stroke. For this, two hypothermia
target temperatures (33 and 34.5◦C) were investigated to identify
the most feasible hypothermia regimen that still effectively
prevented ICP elevation. The “ultra-short” duration refers to
the 30min at target temperatures, which is far shorter than
previous studies of short duration cooling (14). We chose 34.5◦C,
slightly lower than the mildest effective target of 35◦C from
our previous work, to allow for our use of a gradual paradigm
with less time at target temperature than in the previous study.
ICP was measured epidurally using a fiber-optic catheter system.
Epidural measurements were preferred in this study due to the
increased risk of brain damage associated with other methods of
ICP monitoring (19). Any damage to the brain has the potential
to alter ICP, and therefore influence the primary outcome of
this study. Moreover, previous studies have found that epidural
ICP recordings correlate well with intraventricular recordings
(20, 21), which are the “gold standard” of ICP measurements in
humans (19). Additionally, the use of a fiber-optic probe provides
high fidelity ICP signals when inserted and sealed in the epidural
space (19, 22).
MATERIALS AND METHODS
Animals and Experimental Protocol
Adult male (11–12 weeks old) outbred Wistar rats (n = 23,
Animal Services Unit, University of Newcastle) weighing 280–
320 g were used for this study. Animals were housed under
standard conditions in a 12 h light-dark cycle with unlimited
access to food and water. All experimental procedures were in
accordance with the Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes and were approved
by the Animal Care and Ethics Committee of the University of
Newcastle (A-2013-343). This study was reported in accordance
with the ARRIVE guidelines (23).
Rats were initially anesthetised in 5% isoflurane in 50:50
N2:O2 in an induction chamber. Anesthesia was maintained with
2–2.5% isoflurane in the same gasmix and delivered via a custom,
low dead space face mask with cross flow of gases. Incision
sites were shaved, cleaned and injected subcutaneously (s.c.) with
2 mg/kg 0.05% Bupivacaine (Pfizer, Sydney, Australia). Body
temperature was regulated throughout the surgery with a rectal
temperature thermocouple (RET-2, Physitemp Instruments Inc,
Clifton, New Jersey, USA). The femoral artery was cannulated
with a catheter consisting of 1 and 2 French silicone tubing for
continuous monitoring of arterial blood pressure and heart rate
and for measurement of arterial blood gases (i-STAT, Abbot, New
Jersey, USA). Animals were randomized by sealed envelope to
hypothermia treatment (33 or 34.5◦C), or normothermia. After
hypothermia treatment/ normothermia, rectal paracetamol (250
mg/kg, GlaxoSmithKline, Brentford, UK) was administered for
recovery and overnight pain relief. Animals were also injected
with saline (2 × 1.5mL, s.c.) to prevent dehydration and were
returned to their cages with free access to softened laboratory
chow and water.
Implantation of Datalogger Device
A 2 cm longitudinal incision was made along the right abdominal
region, proximal to the right thigh. The incision was made
deep enough to expose the space at the ventral thigh crease.
Haemostats and forceps were used to create a pocket under the
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FIGURE 1 | Experimental protocol (in hours). Baseline intracranial pressure (ICP) recordings were taken for 30min prior to starting MCAo. 0 h signifies the moment of
vessel occlusion. Hypothermia treatment was initiated 1 h after occlusion in the hypothermia groups. Target temperature was achieved 2 h after hypothermia initiation
in the 33◦C group and maintained for 30min. Target temperature was achieved 2.5 h after hypothermia initiation in the 34.5◦C group and maintained for 30min.
Animals in both groups were rewarmed to 35◦C immediately after the maintenance period and recovered from surgical procedures. Normothermia animals were
maintained at 37◦C.
skin that was large enough to hold the device. The temperature
monitoring datalogger (Maxim, San Jose, USA) was inserted into
the pocket and secured by closing the muscle and skin with 5-0
silk sutures. Core body temperature was chosen as the desired
temperature measurement location because it is minimally
invasive and allows for post-operative and overnight monitoring.
Additionally, we have previously compared core, rectal and
brain temperature in rats and found that these temperatures
track together during hypothermia induction, maintenance and
rewarming (unpublished observations).
Intracranial Pressure and Laser Doppler
Measurement
Cranial surgery was performed according to previously described
methods (22). To summarize, the ICP probe (OpSens Fiber
Optic Pressure Sensors, Canada) was inserted epidurally into
a saline filled, polyether ether ketone (PEEK) screw (Bregma
2mm posterior and 2mm lateral) in the left parietal bone. Tissue
perfusion in the territory supplied by the right middle cerebral
artery was monitored during middle cerebral artery occlusion
(MCAo) and reperfusion using laser Doppler flowmetry (LDF).
The LDF probe (Moor Instruments, UK) was inserted into a
second hollow PEEK screw (Bregma 2mm posterior and 5mm
lateral) in the right parietal bone. For ICP and LDF recordings,
the screws were secured with dental cement and an airtight
seal was created around each probe using a caulking material
(Silagum, Gunz Dental, Germany). Correct placement of the ICP
probe was confirmed by a response to abdominal compression
which was observed on both ICP and arterial blood pressure
waveforms. ICP was monitored at pre-stroke baseline and again
at 20–24 h post-stroke (Figure 1). Cerebral perfusion pressure
(CPP) is the difference between mean arterial pressure and ICP,
and was therefore calculated by subtracting these two values. To
account for minor variations between the baseline ICP and CPP
of the 3 experimental groups, change in ICP from baseline to 24 h
(1ICP), and change in CPP from baseline to 24 h (1CPP) were
used for all ICP and CPP analyses.
Middle Cerebral Artery Occlusion
Transient middle cerebral artery occlusion (MCAo) was carried
out according to our established protocol (24, 25). To summarize,
a 6 cm length of monofilament nylon suture (3mm length
× 0.38mm O.D silicone) was inserted into the ligated right
external carotid artery. The filament was advanced 20mm
through the internal carotid artery, avoiding the pterygopalatine
artery, until resistance was felt, and a drop in perfusion units
(>50% drop from baseline) on the LDF was observed which
indicated that the middle cerebral artery has been occluded. At
2 h post-occlusion, reperfusion was achieved by retracting the
monofilament through the internal carotid artery approximately
18mm until the silicone tip was visible in the external carotid
artery stump.
Hypothermia Treatment
After 1 h of MCAo, hypothermia-treated animals were cooled
gradually by reducing the temperature of the heat mat in small
increments (26) to a target core temperature of 33 or 34.5◦C.
Animals were cooled to target over 2 h in the 33◦C group (rate
2◦C/h) and over 2.5 h in the 34.5◦C group (rate 1◦C/h), and
maintained at target for 30min. This gave an overall cooling
duration of 2.5 h and 3 h, respectively. No external cooling
was necessary as anesthesia prevents normal regulation of core
body temperature (Figure 2). For recovery and rewarming, core
body temperature was increased to 35◦C by adjusting the heat
mat. Animals were placed in a cage half over a warming
pad (Passwell, South Australia) to allow for thermoregulation
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FIGURE 2 | Effect of gradual cooling protocol on core body temperature
(datalogger) in rats subjected to hypothermia at 33◦C and 34.5◦C. Vertical
dotted lines at 0 h to 2 h refer to duration of occlusion. Hypothermia was
initiated at 1 h post-occlusion in both 33◦C and 34.5◦C groups. Target
temperature was reached at 3 h post-occlusion in the 33◦C group and 3.5 h
post-occlusion in the 34.5◦C group. “+” indicates rewarming was initiated at
3.5 h in the 33◦C group and “#” indicates rewarming initiation at 4 h in the
34.5◦C group.
back to normothermia. Animals in the 33◦C took 127 ±
36.4min to thermoregulate back to normothermia. Animals in
the 34.5◦C group took 116 ± 39.4min to thermoregulate back
to normothermia. Animals in the normothermia group were
maintained at 37◦C for the duration of the surgery.
Histological Analysis and Infarct Volume
Measurement
Animals were euthanised 24 h post-stroke onset. They were
transcardially perfused with saline and their brains were removed
and sectioned into 6 coronal slices using a rat brain matrix, each
of 2 mm thickness.
Triphenyltetrazolium chloride (TTC) (Sigma-Aldrich,
Missouri, USA) staining was performed to confirm the presence
of ischaemic stroke by identification of infarcted tissue. The
slices from each brain were incubated for 12min at 37◦C in 2%
TTC. TTC was used for early confirmation of infarct, however,
haematoxylin and eosin (H&E) staining was then used on the
same tissue for infarct volume quantification. Infarct volume
quantification was carried out using our routine procedure
(27). Tissues were fixed, processed, paraffin embedded and
cut at 10µm coronal sections. Images were scanned using a
high-resolution scanner (Aperio, Vista, CA, USA) and analyzed
by an investigator blinded to treatment allocation. Infarct
(corrected for oedema) was calculated (Aperio ImageScope) by
subtracting the measured interhemispheric volume difference
from the measured infarct volume for each side. Infarct volumes
were corrected for oedema by applying the formula: corrected
infarct volume (mm3) = infarct volume × (contralateral
volume/ipsilateral volume). Oedema was calculated by infarct
volume minus corrected infarct volume (6).
Exclusion Criteria and Statistical Analysis
Subarachnoid hemorrhage (SAH), equipment malfunction and
lack of >50% LDF drop at occlusion were pre-specified
exclusion criteria.
A sample size calculation was performed using pilot and
previous data (5, 6) (G∗Power version 3.1) which indicated that 4
animals per group were required to detect a 10 mmHg difference
in 1ICP between the hypothermia and normothermia groups
(1ICP = mean peak ICP – mean baseline ICP) with standard
settings of alpha 0.05, power 0.8. A sample size of 5 animals per
group was decided upon to allow for any outlier effects. Statistical
analyses were performed using GraphPad Prism version 8.2.1.
Data were tested for normal distribution using the Shapiro-
Wilk normality test. One-way analyses of variance (ANOVA)
were used to compare differences between the treatment groups
(main effect) followed by Tukey’s post-hoc test for multiple
comparisons between groups when a significant difference was
found. Student’s t-test (paired) were performed to compare
changes from baseline. Statistical significance was accepted at p<
0.05. Data are presented as mean± SD unless otherwise stated.
RESULTS
A total of 15 animals were included in this study: 5 treated with
hypothermia to 33◦C, 5 treated with hypothermia to 34.5◦C and
5 normothermia controls. A total of 8 animals were excluded.
Reasons for exclusion were lack of sufficient LDF drop (n = 5),
SAH detected post-mortem (n = 1) and unexpected death from
surgical complications (n= 2).
Gradual Cooling Slowly Reduces Body
Temperature
Both cooling protocols achieved a gradual decrease of core body
temperature to target (Figure 2). Core temperatures during the
30min at target were 33.2± 0.27◦C and 34.5± 0.22◦C in the two
hypothermia groups. Normothermia animals were maintained at
normal core body temperature for the duration of this period.
In the hypothermia groups, animals reached target at 117.8 ±
26.9min in the 33◦C group and 152.2 ± 2.3min in the 34.5◦C
group. Physiological parameters are presented in Table 1.
Gradual Cooling to 33◦C Prevents ICP
Elevation 24h Post-Stroke
ICP rose significantly from baseline to 24 h in the normothermia
group (1ICP = 8.93 ± 4.82 mmHg: Figure 3A). There was
a significant main effect between treatment groups, F (2, 12)
= 5.1, p = 0.02. Tukey post-hoc test showed that there was
significantly less ICP elevation in the 33◦C group compared to
normothermia, (1ICP = 1.56 ± 2.26 mmHg; p = 0.02). ICP
increased slightly in the 34.5◦C group which resulted in a non-
significant difference when compared to normothermia (1ICP
= 5.32 ± 3.34 mmHg; p = 0.29). CPP decreased significantly
from baseline to 24 h in the normothermia group (1CPP =
−10.21 ± 3.62 mmHg: Figure 3B). There was a significant main
effect between treatment groups, F (2, 12) = 5.461, p = 0.02.
Hypothermia animals in the 33◦C group showed an increase in
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TABLE 1 | Physiological parameters.
Baseline 24 h
Normothermia 33◦C 34.5◦C Normothermia 33◦C 34.5◦C
BP (mmHg) 101.9 ± 8.0 103.0 ± 7.2 103.8 ± 4.8 103.0 ± 7.8 112.8 ± 12.1 98.7 ± 7.4
RR (BPM) 66.9 ± 5.4 63.2 ± 4.8 64.4 ± 4.8 63.0 ± 7.3 60.0 ± 5.1 67.6 ± 12.8
HR (BPM) 421.8 ± 27.6 433.7 ± 22.6 448.1 ± 12.1 386.6 ± 57.9 407.7 ± 18.7 416.4 ± 39.5
SpO2 (%) 100.0 ± 0.8 100.0 ± 1.1 100.0 ± 0.5 99.6 ± 1.4 99.7 ± 1.8 99.2 ± 2.1
Temp. (◦C) 37.1 ± 0.2 37.1 ± 0.3 36.8 ± 0.2 37.1 ± 0.2 37.0 ± 0.3 36.8 ± 0.2
paO2 (mmHg) 191.0 ± 4.6 213.2 ± 23.3 194.2 ± 37.3 163.3 ± 23.44 195.2 ± 22.91 180.6 ± 20.86
paCO2 (mmHg) 52.7 ± 2.1 64.5 ± 11.8 62.8 ± 4.8 52.3 ± 4.6 49.5 ± 6.6 63.0 ± 17.6
pH 7.35 ± 0.03 7.23 ± 0.05 7.29 ± 0.02 7.41 ± 0.03 7.40 ± 0.02 7.35 ± 0.10
BP, mean arterial blood pressure; RR, respiratory rate; HR, heart rate; SPO2, oxygen saturation; Temp, temperature; paO2, arterial partial pressure of oxygen; paCO2, arterial partial
pressure of carbon dioxide. Presented for illustrative purposes only.
CPP from baseline to 24 h when compared to normothermia
(1CPP= 6.35± 9.33 mmHg, p= 0.04). Hypothermia animals in
the 34.5◦C group showed no difference in CPP when compared
with normothermia (1CPP=−11.93± 13.41mmHg, p= 0.96).
Gradual Cooling to 33◦C Reduced Infarct
Volume 24h Post-Stroke
There was a significant main effect between treatment groups,
F (2, 12) = 8.338, p = 0.005- (Figure 4). Hypothermia treated
animals to 33◦C had significantly smaller infarct volumes than
normothermia controls (46.4 ± 12.3 mm3 and 85.0 ± 17.5
mm3, respectively, p = 0.01). Hypothermia treated animals to
34.5◦C did not have smaller infarct volumes when compared
to normothermia controls (87.2 ± 22.1 mm3 p = 0.98).
Representative images are also presented in Figure 4.
DISCUSSION
In this study, we have shown that clinically achievable gradual
cooling to 33◦C, with only 30min at target temperature,
prevented significant elevation of ICP and reduced infarct
volume 24 h post-stroke. We have previously shown that 2.5 h
hypothermia to 32.5◦C prevented ICP rise at 24 h in both young
adult and aged rats, and in different strains (6, 7). In these
previous studies, a target temperature of 32.5◦C was achieved
within 20min and rats were maintained at target for 130min
(the remainder of the 2.5 h duration) before being rewarmed.
This current study suggests that hypothermia has the same ICP
rise prevention properties as previously shown (5–7), even when
using a clinically achievable cooling rate with a shorter duration
at target temperature.
The results of this study support previous work indicating
a likely link between ICP rise prevention and neuroprotection,
resulting from hypothermia. Following an ischaemic stroke, the
penumbra is kept temporarily viable by perfusion from the
collateral vessels. The blood flow to the ischaemic penumbra is
known to be dependent on CPP: the difference between mean
arterial pressure and ICP. ICP elevation after stroke causes a
reduction in CPP, which thereby reduces blood flow to the
penumbra and may be responsible for infarct expansion (6, 9).
Preliminary data on human stroke patients also demonstrate an
ICP rise 24 h post-stroke (8). At the same time, we have shown
that a short period of moderate hypothermia in rats prevents ICP
rise, even in the presence of large strokes (7). Previous studies
have also shown that hypothermia-treated animals with no ICP
elevation also tend to have smaller infarct volumes at 24 h than
their normothermia counterparts (5, 6).
In this present study, we have shown that hypothermia to
34.5◦C did not significantly prevent ICP elevation or reduce
infarct volume. These results have important implications
because it suggests that a longer duration at target temperature
might be necessary for milder hypothermia (≥34.5◦C).
Previous animal studies have shown that hypothermia to target
temperatures as mild as 35◦C for 2 h reduces infarct volume (14).
However, there does appear to be a depth-response relationship
in which lower temperatures provide greater benefit (28, 29).
The lack of efficacy seen in the 34.5◦C group in this study is likely
due to the ultra-short duration for which target temperature was
maintained. This finding suggests that, for a much slower cooling
rate, either a greater temperature depth or a longer duration at
target temperature is likely required to show benefit. However, at
a target temperature of 33◦C we found that a short duration of
30min had similar protective effects on ICP elevation and infarct
volume to those shown in studies where target temperature is
maintained for longer periods (5–7).
While there are some data suggesting that longer durations
of cooling may be required for neuroprotection when the
onset of hypothermia is delayed (30, 31), it is evident from
experimental studies that a prolonged period of treatment is
not necessary when hypothermia is initiated shortly after vessel
occlusion and during reperfusion. However, additional studies
will be required to determine how long the interval from stroke
onset to treatment can be, while still maintaining effectiveness.
Previous studies by our group (5–7) and this present study
have initiated hypothermia 1 h after vessel occlusion and have
demonstrated ICP rise prevention at 24 h. The fact that we
were still able to see such robust effects with a very short
duration at target temperature suggests that perhaps the most
important parameter is reaching target temperature and not
necessarily the amount of time spent at target. While a 30min
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FIGURE 3 | (A) Change in ICP from baseline to 24h in the 33◦C and 34.5◦C hypothermia groups and normothermia control. (B) Change in CPP from baseline to 24 h
in the 33◦C and 34.5◦C hypothermia groups and normothermia control. * denotes statistical significance where p < 0.05.
FIGURE 4 | (A) Infarct volume from H&E staining at 24 h measured in all groups. * denotes statistical significance where p < 0.05, ** denotes statistical significance
where p < 0.01. (B) Representative H&E images of infarct size of (1) normothermia controls, (2) hypothermia 33◦C and (3) hypothermia 34.5◦C animals at 24 h
post-stroke. Dotted gray lines indicate region of infarct. Scale bar = 4mm.
duration at 33◦C was used in this study, it is possible that we
may have achieved the same results had we cooled to target
temperature and immediately rewarmed. This short-duration
approach couldmake hypothermiamuchmore clinically feasible,
as the therapy can be initiated at the time of sedation for
endovascular thrombectomy, for example.
Our results have demonstrated that clinically relevant cooling
rates are feasible and effective in rats. The rate of cooling is an
important factor from a translational standpoint and is often not
the focus in experimental stroke studies utilizing hypothermia. It
has been well documented that humans take considerably longer
to cool to target temperature than rodents because of differences
in surface area to volume ratio (26). Target temperature is
achieved very rapidly in animals; for example, previous work
from our group has shown that a target temperature of 32.5◦C
can be achieved within 20min (5). This gives us a rate of
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0.23◦C/min or 13.8◦C/h. This is clearly not comparable to human
cooling rates, for example the endovascular cooling feasibility
study by Georgiadis et al. found that the cooling rate for stroke
patients to reach a target temperature of 33◦C was 1.4 ± 0.6◦C/h
(32). The gradual cooling model used in this present study is
a major improvement for animal studies with a cooling rate of
2◦C/h in the 33◦C group and 1◦C/h in the 34.5◦C group.
We have demonstrated, using a novel method of gradual
hypothermia coupled with intensive temperature monitoring,
that cooling rates shown to be achieved in humans, can also
be achieved in rats. A limitation of this study was that we did
not use the same endovascular cooling method that is common
in human hypothermia trials. However, there are currently
no methods available in small animals that precisely mimic
endovascular cooling in humans. Another limitation of this study
is that we did not explore whether the robust neuroprotection
of hypothermia extends beyond the 24 h observational window.
However, the 24 h timepoint is important because it is when
ICP elevation peaks post-stroke (5–7). Investigations into the
long-term efficacy of hypothermia beyond 24 h will be the focus
of future studies. Additionally, further studies will be required
to explore the efficacy of short-duration cooling to 34.5◦C.
This milder temperature may have more robust effects on ICP
elevation and infarct volume than was shown in this study if
for example, a longer duration at target temperature was used.
Neurological deficit assessments were not included in this study.
While it is important to determine whether the neuroprotection
offered by hypothermia to 33◦C extends to neurological deficits,
we were powered based on our primary outcome of 1ICP,
not neurological deficit scores. Sample size calculations for
neurological scores or other behavioral measures would result in
much larger group sizes (33).
Lastly, there was a brief occurrence of post-operative
hypothermia in all groups in which core body temperature
dropped for a short period after rewarming. However, post-
operative hypothermia is a universal phenomenon that occurs
(34) but is often not measured. While every effort was made
to ensure adequate rewarming in the hypothermia groups, the
fact that we also saw this dip in temperature occur in our
normothermia controls suggest that it is not a factor that
influenced the results obtained.
In conclusion, long durations of cooling and their resulting
complications have limited large-scale clinical trials and would
likely limit the application of long-duration hypothermia as a
widely used therapy in stroke. Achieving target temperature
has been a challenge in clinical trials of hypothermia in stroke;
however, this step may be critical to patient outcome. The lack
of benefit seen at 34.5◦C highlights the critical importance of
achieving target temperature. Recent results from one of the
most prominent early-phase clinical trials of hypothermia for
ischaemic stroke (EuroHYP-1) found that only 31% of patients
recruited achieved target temperature (34–35◦C) and suggest
this as a potential reason for the lack of benefit reported in the
study (35). There is only a 1.5◦C difference in target temperature
between the two treatments groups in the present study, yet
we have shown a dramatic difference in outcome between the
groups. This narrow window of effect may also be present in
humans, therefore ensuring that target temperature is achieved
may have significant impacts on patient outcome. Moreover,
the effectiveness of only 30min at 33◦C highlights the fact
that much shorter durations of cooling than those used in
clinical trials may be effective with early treatment initiation.
In recent years, methods have been well established to achieve
rapid cooling in patients using whole-body techniques such as
endovascular or skin cooling (15). Direct brain cooling strategies
such as intranasal (36) and intracarotid cooling (37) are less well
established but are under investigation.
Our results suggest that a very short time period at 33◦C
may be all that is necessary to prevent significant ICP elevation
and reduce infarct volume if cooling is initiated early. Further
definition of the time window for treatment initiation will be
needed, however, these results raise the prospect of benefit from
a far more feasible hypothermia paradigm that has previously
been tested, and hope that the long-recognized neuroprotective
benefits may be able to be realized for stroke patients.
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